A federal judge in Delaware has ruled in favor of Exelixis in its Cabometyx patent fight with MSN Laboratories, effectively pushing the earliest generic entry out to 2030. After a four-day bench ...

Exelixis (NASDAQ:EXEL) jumped 6% after winning in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claim of the '349 patent not infringed and not invalid ...

Exelixis (NASDAQ:EXEL) jumped 9% after a win in a patent fight with generic drug make MSN Laboratories over Cabometyx. The asserted claims of the Malate Salt Patents are not invalid, Judge Richard G.

The adjustment follows a recent court decision that upheld the patent protection for the company's cancer drug, Cabometyx (Cabo), extending its market exclusivity until 2030. The analyst at RBC ...

When you buy through our links, Business Insider may earn an affiliate commission. Learn more T-shirts are quintessential for any wardrobe, especially during the spring and summer. They're a ...

Probably best known for the cancer drug Cabometyx (cabozantinib), which is marketed by Ipsen outside of the US and Japan, Exelixis already has four small-molecule drugs on the market. But CEO ...

A federal judge in Delaware upheld the validity of three patents for Exelixis Inc.’s Cabometyx that MSN Laboratories Private Ltd. had conceded its generic version of the blockbuster cancer drug ...

MSN is seeking approval for a product containing a different polymorphic form of cabozantinib (l)-malate than the form contained in Exelixis’ breakthrough CABOMETYX ® (cabozantinib) product. To ...